Some advantages of using RNA as an antigen include the absence of a biological risk of infection and the possibility of designing a sequence restricted to targeting MHC class I or II molecules, thus activating immune responses to CD8+ T cells or both CD4+ and CD8+ T cells, respectively. This evidence concerns the gene CD8A and infection.